Intravascular brachytherapy: indications and management of adverse events.
Intravascular brachytherapy has become the standard of care for the treatment of coronary in-stent restenosis after repeat angioplasty. More than 5000 patients have been treated as part of various clinical trials. Based on the results of the GAMMA I trial, the START ((90)Sr Treatment of Angiographic Restenosis Trial), and the INHIBIT (INtimal Hyperplasia Inhibition with Beta In-stent restenosis Trial), the Checkmate system using (192)Ir, the Betacath system using (90)Sr/Y, and the Galileo system using (32)P, have been approved for the treatment of in-stent restenosis. With a better understanding and application of radiation oncology concepts to vascular brachytherapy, problems such as edge failure are being overcome. The complication of late thrombosis has also become less significant with the elimination of restenting at the brachytherapy procedure, and the prolonged use of antiplatelet therapy. There are other competing modalities in the early phases of clinical trials. The durability of results, lack of any significant long-term complications and the confirmation of the efficacy in other sites will further consolidate the role of radiation in treating in-stent restenosis.
Bhargava
Balram
B
Department of Cardiology, Cardiothoracic Sciences Centre, All India Institute of Medical Sciences, New Delhi, India. balrambhargava@yahoo.com
Karthikeyan
Ganesan
G
Tripuraneni
Prabhakar
P
D001610:Beta Particles; D001918:Brachytherapy / Q000009:adverse effects* / Q000379:methods*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control / Q000532:radiotherapy; D023921:Coronary Stenosis / Q000532:radiotherapy*; D005720:Gamma Rays; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000532:radiotherapy*; D016032:Randomized Controlled Trials as Topic; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000209:etiology